Business
Statement re broker
Statement re broker.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 5358G ValiRx PLC 02 March 2018 \n\n \nVALIRX PLC\n(\"ValiRx\", the \"Company\" or the \"Group\")\n \nStatement re broker\nThe Company notes the announcement today regarding Beaufort Securities Limited (\"BSL\") and Beaufort Asset Clearing Services Limited (\"BACSL\") being placed into insolvency and that the Financial Conduct Authority (the \"FCA\") has imposed requirements on BSL and BACSL to cease all regulatory activity.\nBSL is the broker to the Company pursuant to the AIM Rules for Companies (the \"AIM Rules\"). As a result of the requirements imposed by the FCA, BSL will no longer be able to provide broking services to the Company in accordance with the AIM Rules.\nThe Company is seeking to appoint a new broker as soon as possible and a further announcement will be made when this appointment is made.\n*** ENDS ***\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser) \nLiam Murray/Jo Turner/Richard Nash\n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\n \nNotes for Editors\nAbout ValiRx \nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\nThe Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. \nValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College...